Arsenic trioxide circumvents multidrug resistance based on different mechanisms in human leukemia cell lines

Anticancer Research

Volumn 25, Issue 2 A, 2005, Pages 991-998

  Seo, Tamami ^a   Urasaki, Yoshimasa ^a   Takemura, Haruyuki ^a   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Arsenic trioxide; Buthionine sulfoximine; Glutathione; Multidrug resistance; Reactive oxygen species

Indexed keywords

ARSENIC TRIOXIDE; BUTHIONINE SULFOXIMINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GLUTATHIONE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BCL 2; VERLUKAST; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CELL STRAIN; CELL STRAIN D1 9; CELL STRAIN HL 60; CELL STRAIN K 562; CROSS RESISTANCE; GENE OVEREXPRESSION; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BUTHIONINE SULFOXIMINE; CELL GROWTH PROCESSES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENES, BCL-2; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LEUKEMIA, PRE-B-CELL; LEUKEMIA, PROMYELOCYTIC, ACUTE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; OXIDES; P-GLYCOPROTEIN; REACTIVE OXYGEN SPECIES; TRANSFECTION;

EID: 17444388907     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360, 1997.
2. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang T, Waxman S, Wang ZY, Chen SJ et al: Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94: 3315-3324, 1999.
3. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP and Warrell RP Jr: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339: 1341-1348, 1998.
4. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88: 1052-1061, 1996.
5. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C and Miller WH Jr: Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 90: 124-133, 1998.
6. Zhu J, Koken MH, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, Chen Z and de The H: Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 94: 3978-3983, 1997.
7. Zhang Y and Nie L: Studies of apoptosis of malignant lymphoma cells induced by arsenic trioxide. Cell Biol Int 25: 1003-1006, 2001.
8. Zhang TC, Cao EH, Li JF, Ma W and Qin JF: Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer 55: 1258-1263, 1999.
9. Akao Y, Nakagawa Y and Akiyama K: Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 455: 59-62, 1999.
10. Zhou DC, Zittoun R and Marie JP: Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia 9: 1661-1666, 1995.
11. Urasaki Y, Ueda T, Yoshida A, Fukushima T, Takeuchi N, Tsuruo T and Nakamura T: Establishment of a daunorubicin-resistant cell line which shows multi-drug resistance by multifactorial mechanisms. Anticancer Res 16: 709-714, 1996.
12. Takemura H, Urasaki Y, Yoshida A, Fukushima T and Ueda T: Simultaneous treatment with 1-beta-D-arabino furanosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells. Cancer Res 61: 172-177, 2001.
13. Miyashita T and Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81: 151-157, 1993.
14. Darzykiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P and Traganos F: Features of apoptotic cells measured by flow cytometry. Cytometry 13: 795-808, 1992.
15. Bagrij T, Klokouzas A, Hladky SB and Barrand MA: Influences of glutathione on anionic substrate efflux in tumour cells expressing the multidrug resistance-associated protein, MRP1. Biochem Pharmacol 62: 199-206, 2001.
16. Gekeler V, Ise W, Sanders KH, Ulrich WR and Beck J: The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun 208: 345-352, 1995.
17. Perkins C, Kim CN, Fang G and Bhalla KN: Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood 95: 1014-1022, 2000.
18. 3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance. Eur J Haematol 66: 357-364, 2001.
19. Salerno M, Petroutsa M and Garnier-Suillerot A: The MRP1-mediated effluxes of arsenic and antimony do not require arsenic-glutathione and antimony-glutathione complex formation. J Bioenerg Biomembr 34: 135-145, 2002.
20. Wei H, Su H, Bai D, Zhao H, Ge J, Wang B, Yao X and Ma L: Arsenic trioxide inhibits p-glycoprotein expression in multidrug-resistant human leukemia cells that overexpress the MDR1 gene. Chin Med J (Engl) 116: 1644-1648, 2003.
21. Danks MK, Yalowich JC and Beck WT: Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res 47: 1297-1301, 1987.
22. Nakagawa Y, Akao Y, Morikawa H, Hirata I, Katsu K, Naoe T, Ohishi N and Yagi K: Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci 70: 2253-2269, 2002.
23. Vernhet L, Allain N, Payen L, Anger JP, Guillouzo A and Fardel O: Resistance of human multidrug resistance-associated protein 1-overexpressing lung tumor cells to the anticancer drug arsenic trioxide. Biochem Pharmacol 61: 1387-1391, 2001.
24. Lorico A, Bertola A, Baum C, Fodstad O and Rappa G: Role of the multidrug resistance protein 1 in protection from heavy metal oxyanions: investigations in vitro and in MRP1-deficient mice. Biochem Biophys Res Commun 291: 617-622, 2002.
25. Dai J, Weinberg RS, Waxman S and Jing Y: Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93: 268-277, 1999.
26. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG and Waxman S: Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94: 2102-2111, 1999.
27. Kramer RA, Zakher J and Kim G: Role of the glutathione redox cycle in acquired and de novo multidrug resistance. Science 241: 694-697, 1988.
28. Scott N, Hatlelid KM, MacKenzie NE and Carter DE: Reactions of arsenic(III) and arsenic(V) species with glutathione. Chem Res Toxicol 6: 102-106, 1993.
29. Yang CH, Kuo ML, Chen JC and Chen YC: Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 81: 796-799, 1999.
30. Ruiz-Gomez MJ, Souviron A, Martinez-Morillo M and Gil L: P-glycoprotein, glutathione and glutathione S-transferase increase in a colon carcinoma cell line by colchicine. J Physiol Biochem 56: 307-312, 2000.
31. Benderra Z, Trussardi A, Morjani H, Villa AM, Doglia SM and Manfait M: Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein. Eur J Cancer 36: 428-434, 2000.
32. Kito M, Akao Y, Ohishi N, Yagi K and Nozawa Y: Arsenic trioxide-induced apoptosis and its enhancement by buthionine sulfoximine in hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 291: 861-867, 2002.
33. Liu J, Chen H, Miller DS, Saavedra JE, Keefer LK, Johnson DR, Klaassen CD and Waalkes MP: Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol Pharmacol 60: 302-309, 2001.
34. Wartenberg M, Ling FC, Schallenberg M, Baumer AT, Petrat K, Hescheler J and Sauer H: Down-regulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by reactive oxygen species. J Biol Chem 276: 17420-17428, 2001.
35. Gamcsik MP, Kasibhatla MS, Adams DJ, Flowers JL, Colvin OM, Manikumar G, Wani M, Wall ME, Kohlhagen G and Pommier Y: Dual role of glutatione in modulating camptothecin activity: depletion potentiates activity, but conjugation enhances the stability of the topoisomerase 1-DNA dleavage complex. Mol Cancer Therap 1: 11-20, 2001.
36. Vanhoefer U, Cao S, Minderman H, Toth K, Skenderis BS 2nd, Slovak ML and Rustum YM: d,1-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Clin Cancer Res 2: 1961-1968, 1996.
37. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H, Sahara N, Takeshita A, Satoh H, Terada H and Ohno R: Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia 16: 617-622, 2002.